| Today’s Big NewsApr 1, 2024 |
| By Gabrielle Masson The biotech industry has been holding its breath, hoping that 2024 would bring some reprieve from 2023’s brutal bear market. But market recovery is a slow process, and the number of layoffs reported this quarter reflect that sentiment, with 57 layoff rounds reported for the first three months—the exact number reported during the same period last year. |
|
|
|
By Max Bayer Equillium’s add-on lupus treatment improved a biomarker of kidney function in an unblinded phase 1 study, setting the ball rolling toward Ono Pharmaceuticals’ court for future development work. |
By Annalee Armstrong Days after Regeneron received a complete response letter for the blood cancer medicine odronextamab, hematology executive Andres Sirulnik says the trial is enrolling just fine—it’s just that randomization hasn’t begun. |
By Helen Floersh Researchers for the first time have identified dysfunctional immune cells in the healthy breast tissue of women with mutations in the genes BRCA1 and BRCA2, a finding that opens up the possibility of using existing immunotherapy drugs to prevent cancer before it forms. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Angus Liu What analysts viewed as a potential “inflection point” for Eisai and Biogen’s slow-footed Leqembi is facing a delay with the FDA. |
By Zoey Becker While the drug is not listed on the FDA's shortage list, some pharmacies are facing supply issues. Amazon Pharmacy, for instance, notes that several dosage strengths are "unavailable." |
By Conor Hale You won’t see Abbott’s i-STAT Alinity test on the sidelines of sporting events just yet—but the FDA’s green light is a step in that direction, allowing the use of whole blood samples. |
By Eric Sagonowsky Shortly after Gilead Sciences teamed up with Carlyle’s Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar pathway for an asthma rescue inhaler. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. |
|
|---|
|
|
|
Available On-Demand Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Access this discussion on-demand to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. View now.
|
|
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
